Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720263 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02720263 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 48 participants.
The verdict
NCT02720263, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia. In addition, this study will evaluate the pharmacokinetics of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
Interventions
- DRUG Matching Placebo
- DRUG ASP4345
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-03-28 |
| Est. Completion | 2017-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720263
The ClinicalTrials.gov registry entry for NCT02720263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02720263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720263 about?
NCT02720263 is a clinical study titled "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia". The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia. In addition, this study will evaluate the pharmacokinetics of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
What is the current status of trial NCT02720263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-03-28. Estimated completion is 2017-06-08.
What interventions are being tested in trial NCT02720263?
The interventions under investigation include: Matching Placebo (DRUG), ASP4345 (DRUG).
Who is sponsoring clinical trial NCT02720263?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.